Annji Pharmaceutical Co (ROCO:7754) Total Equity: NT$319.82 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7754 Annji Pharmaceutical Co Ltd ROCO:7754
9 GF Score
Price NT$59.90
! 6 Warning Signs
View Full Analysis

What is Annji Pharmaceutical Co Total Equity?

Annji Pharmaceutical Co ROCO:7754 +0.50% 9 Total Equity is NT$319.82 Mil as of Dec. 2025. GuruFocus rates ROCO:7754 with a GF Score™ of 9/100. The stock has 6 warning signs investors should review.

Annji Pharmaceutical Co's total equity for the quarter that ended in Dec. 2025 was NT$319.82 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Annji Pharmaceutical Co Total Equity Historical Data

* Premium members only.

The historical data trend for Annji Pharmaceutical Co's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Annji Pharmaceutical Co Total Equity Chart

Annji Pharmaceutical Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
650.13 510.51 925.04 662.10 319.82

Annji Pharmaceutical Co Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial 925.04 809.42 662.10 510.25 319.82
ROCO:7754
9GF Score
Annji Pharmaceutical Co Ltd ROCO:7754
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Annji Pharmaceutical Co Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Annji Pharmaceutical Co's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=590.109-270.287
=319.82

Annji Pharmaceutical Co's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=590.109-270.287
=319.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of NT$319.82 Mil mean?
Annji Pharmaceutical Co (ROCO:7754) has a Total Equity of NT$319.82 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Annji Pharmaceutical Co and its competitors.
Is Annji Pharmaceutical Co's Total Equity too high?
Annji Pharmaceutical Co's current Total Equity is NT$319.82 Mil. Overall, Annji Pharmaceutical Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Annji Pharmaceutical Co's Total Equity compare to VRTX and REGN?
Annji Pharmaceutical Co's Total Equity of NT$319.82 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Annji Pharmaceutical Co and its competitors. Annji Pharmaceutical Co's current Total Equity is NT$319.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annji Pharmaceutical Co stock overvalued right now?
Annji Pharmaceutical Co (ROCO:7754) has a current Total Equity of NT$319.82 Mil. The current Total Equity is NT$319.82 Mil. Annji Pharmaceutical Co's overall GF Score™ is 9/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Annji Pharmaceutical Co (ROCO:7754), the current Total Equity is NT$319.82 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Annji Pharmaceutical Co Business Description

Address Zhongxiao E. Raod, 16th Floor-6, No. 508, Sector 7, Nangang Distrist, Taipei, TWN, 115011
Annji Pharmaceutical Co Ltd is an R&D based, clinical-stage new drug company dedicated to the development of first-in-class small molecules focusing on indications with highly unmet needs in the therapeutic areas of neurology, dermatology, and inflammatory disorders, including rare diseases such as idiopathic pulmonary fibrosis and Kennedy's disease, or SBMA (Spinal and bulbar muscular atrophy). Its pipeline products include AJ201, AJ302 and AJ303.
9GF Score

Get the complete analysis for ROCO:7754

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$59.90
Price